Yahoo
NYSE - Delayed Quote USD

Abbott Laboratories (ABT)

106.20 +1.63 (+1.56%)
At close: October 30 at 4:02:15 PM EDT
106.25 +0.05 (+0.05%)
After hours: October 30 at 7:21:18 PM EDT
Trade ABT on Coinbase
Chart Range Bar
Loading chart for ABT

What's happening with ABT?

15m ago
Powered by Yahoo Scout

Abbott Laboratories is balancing a planned Nutrition business spin-off by 2027against continued investment in medical devices and diagnostics. The company also advanced its investigational Cephea mitral-valve device into a pivotal trial, while industry reports point to expanding markets for point-of-care testing. ABT was up 1.56% in the current regular sessionon October 30, 2026.

Powered by Yahoo Scout
  • Previous Close 104.57
  • Open 106.15
  • Bid 105.90 x 40000
  • Ask 106.50 x 10000
  • Day's Range 104.60 - 106.85
  • 52 Week Range 81.97 - 132.03
  • Volume 8,439,574
  • Avg. Volume 8,763,784
  • Market Cap (intraday) 183.767B
  • Beta (5Y Monthly) 0.58
  • PE Ratio (TTM) 39.48
  • EPS (TTM) 2.69
  • Earnings Date Oct 21, 2026
  • Forward Dividend & Yield 2.52 (2.41%)
  • 1y Target Est 118.52
  • Morningstar Rating Rating available with Stock Picks access

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company offers generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, hypertriglyceridemia, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon. It also provides laboratory and transfusion medicine systems in the areas of immunoassay, clinical chemistry, hematology, and transfusion serology testing; molecular diagnostics polymerase chain reaction instrument systems that automate the extraction, purification, and preparation of DNA and RNA from patient samples, and detect and measure infectious agents; point of care systems; cartridges for testing blood gas, chemistry, electrolytes, coagulation, and immunoassay; rapid diagnostics lateral flow testing products; molecular point-of-care testing for HIV, SARS-CoV-2, influenza A and B, RSV, and strep A; cardiometabolic test systems; and drug and alcohol test. In addition, the company offers pediatric and adult nutritional products and infant formula; rhythm management, electrophysiology, heart failure, vascular, and structural heart devices for the treatment of cardiovascular diseases; diabetes care products, such as glucose and blood glucose monitoring systems; and neuromodulation devices. The company was formerly known as Abbott Alkaloidal Company and changed its name to Abbott Laboratories in 1915. Abbott Laboratories was founded in 1888 and is based in Abbott Park, Illinois.

www.abbott.com

122,000

Full Time Employees

December 31

Fiscal Year Ends

Healthcare

Sector

Medical Devices

Industry

Recent News

View More

Performance Overview

Trailing total returns as of 10/30/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .

YTD Return

ABT
13.13%
S&P 500 (^GSPC)
10.73%

1-Year Return

ABT
12.70%
S&P 500 (^GSPC)
11.11%

3-Year Return

ABT
21.63%
S&P 500 (^GSPC)
81.91%

5-Year Return

ABT
8.98%
S&P 500 (^GSPC)
64.59%

Earnings Trends

View More

Earnings Per Share

GAAP
Normalized
GAAP
Normalized

Revenue vs. Earnings

Annual
Quarterly
Annual
Quarterly
Q3 FY26
Revenue 13.01B
Earnings 920M
Profit Margin 7.07%

Q4

FY25

Q1

FY26

Q2

FY26

Q3

FY26

0
5B
10B
8.0%
10.0%
12.0%
14.0%

Analyst Insights

View More

Analyst Price Targets

100.00 Low
118.52 Average
106.20 Current
130.00 High

Analyst Recommendations

  • Strong Buy
  • Buy
  • Hold
  • Underperform
  • Sell

Latest Rating

Date 10/27/2026
Analyst Argus Research
Rating Action Downgrade
Rating Hold
Price Action --
Price Target --

Statistics

View More

Valuation Measures

Annual
  • Market Cap

  • Enterprise Value

  • Trailing P/E

  • Forward P/E

  • PEG Ratio (current)

  • Price/Sales (ttm)

  • Price/Book (mrq)

  • Enterprise Value/Revenue

  • Enterprise Value/EBITDA

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    9.75%

  • Return on Assets (ttm)

    --

  • Return on Equity (ttm)

    --

  • Revenue (ttm)

    48.23B

  • Net Income Avi to Common (ttm)

    4.68B

  • Diluted EPS (ttm)

    2.69

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    5.6B

  • Total Debt/Equity (mrq)

    63.21%

  • Levered Free Cash Flow (ttm)

    --

Company Insights

Research Reports

View More

People Also Watch

Mobilize your Website
View Site in Mobile | Classic
Share by: